For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com  Inclusion Criteria:  Diagnosis of recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) Age ≥18 years at time of nivolumab treatment initiation Investigator has decided that nivolumab is appropriate therapy and the participant had received at least one administration of nivolumab for the treatment of recurrent/metastatic SCCHN prior to enrolment in the study Charts/records include treatment start date of nivolumab Provide consent and is willing to self-complete on-site patient reported outcomes (PROs) on at least one occasion  Exclusion Criteria:  Currently enrolled in an interventional clinical trial for their SCCHN Received systemic treatment for any other primary cancer within 6 months of study enrolment